Drug Trial Radar · NCT04401059
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
Last checked: Nov 19, 2026Latest source record: Dec 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
744
Planned (sponsor's estimate)
Start
Nov 9, 2020
Primary completion
Sep 30, 2025
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Tian XieAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- LinkDoc Technology (Beijing) Co. Ltd.
- First posted
- May 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
Conditions
- Carcinoma
- Non-Small-Cell Lung Cancer
- Adenocarcinoma
Interventions
Elemene plus first or third generation EGFR-TKIsDrug
Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label. Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason. First or third generation EGFR-TKIs: refer to the drug label.
First or third generation EGFR-TKIsDrug
refer to the drug label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: Start of treatment until 1-year follow-up
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, China · Recruiting
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China · Recruiting
Panjin Central Hospital
Panjin, Liaoning, China · Recruiting
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China · Recruiting
The Second People's Hospital of Yangcheng County
Jincheng, Shanxi, China · Recruiting
Sichuan Academy of Medical Sciences· Sichuan Province People's Hospital
Chengdu, Sichuan, China · Recruiting
Hangzhou Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.